摘要
目的为评价现有疫苗接种后可能出现的不良事件,为行政部门制定切合杭州实际接种后不良事件补偿办法提供基础数据。方法应用2004年被动监测数据,分析不同疫苗的不良事件发生率,并比较针对相同疾病的不同制剂的不良事件发生率。结果全市总体接种后不良事件发生率为61.77/10万;其中以某公司的23价肺炎疫苗的接种后不良事件发生率最高达509.19/10万;在接种后不良事件中,硬结以45.75%高居第一;发热以40.45%位居第二。二者共占所有接种后不良事件的86.20%。结论不同生物制品之间接种后不良事件发生率差异很大。但城区和郊县的接种后不良事件发生率没有明显差异。
Objective The present study was designed to evaluate the adverse events that were likely to occur after vaccination with the available vaccines in order to provide essential data for the administrations to formulate the compensations, which suit the actual conditions of Hangzhou, for the adverse events caused by vaccinations. Methods The data from passive surveillance in 2004 were used to analyze the incidences of adverse events caused by different vaccines and compare the incidences of adverse events caused by the preparations for the same disease. Results The total incidence of post-vaccination adverse events was 61.77/lakh in the city, with the 23- valent pneumonia vaccine manufactured by a certain company causing the highest incidence （509.19/lakh）.Indurations and fever accounted for 45.75% and 40.45% of the post-vaccination adverse events and were ranked as the first and second respectively in the list, both events together constituting 86.20% of all the post-vaccination adverse events. Conclusion There is a significant difference in the incidence of post-vaccination adverse events between different bioproducts. But no significant difference was seen in the incidence between the urban areas and suburban counties.
出处
《疾病监测》
CAS
2006年第12期657-659,共3页
Disease Surveillance
关键词
预防接种
不良事件
分析
vaccination
adverse events
analysis
